From 23 to 26 February 2026, CARBOGEN AMCIS will be exhibiting at World ADC London 2026 at Royal Victoria Dock, London, together with its new strategic partner, Celonic Group.
This joint presence marks an important step in delivering a fully integrated antibody drug conjugate (ADC) development and manufacturing platform. By combining Celonic’s advanced biologics capabilities with CARBOGEN AMCIS’ expertise in highly potent payload synthesis, drug-linker development, bioconjugation and sterile fill-finish, the alliance offers ADC innovators a seamless, end-to-end solution from early development through to commercial supply.
ADC programmes are inherently complex, often requiring multiple specialist vendors across drug substance and drug product. By aligning complementary strengths within a single, coordinated partnership, Celonic and CARBOGEN AMCIS aim to streamline supply chains, reduce risk and accelerate timelines.
CARBOGEN AMCIS brings more than 40 years of CDMO expertise across drug substance and sterile drug product manufacturing, including dedicated high-containment facilities and state-of-the-art aseptic capabilities in Saint-Beauzire, France. The company’s experience in ADC payload manufacturing, conjugation and fill-finish is supported by integrated analytical services and a robust technology transfer framework.
Together with Celonic’s biologics platform, this strategic alliance creates a fully connected development pathway designed to support the growing demands of the global ADC pipeline.
If you are advancing an ADC programme and looking to simplify your development journey, visit CARBOGEN AMCIS and Celonic at booth #61 to discuss your project with their expert team.
Book a meeting in advance or stop by during the event to explore how an integrated ADC platform can help bring your next therapy to market with confidence.
https://www.carbogen-amcis.com/events/worldadclondon
